CN104271142B - 含有α连接蛋白C‑末端(ACT)肽的局部凝胶 - Google Patents

含有α连接蛋白C‑末端(ACT)肽的局部凝胶 Download PDF

Info

Publication number
CN104271142B
CN104271142B CN201380023492.XA CN201380023492A CN104271142B CN 104271142 B CN104271142 B CN 104271142B CN 201380023492 A CN201380023492 A CN 201380023492A CN 104271142 B CN104271142 B CN 104271142B
Authority
CN
China
Prior art keywords
alpha connexin
seq
topical formulation
wound
connexin polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380023492.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN104271142A (zh
Inventor
G·格哈特尼卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xequel Bio Inc
Original Assignee
FirstString Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FirstString Research Inc filed Critical FirstString Research Inc
Publication of CN104271142A publication Critical patent/CN104271142A/zh
Application granted granted Critical
Publication of CN104271142B publication Critical patent/CN104271142B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
CN201380023492.XA 2012-03-01 2013-03-01 含有α连接蛋白C‑末端(ACT)肽的局部凝胶 Active CN104271142B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261605528P 2012-03-01 2012-03-01
US61/605,528 2012-03-01
PCT/US2013/028727 WO2013131040A1 (en) 2012-03-01 2013-03-01 Topical gels containing alpha connexin c-terminal (act) peptides

Publications (2)

Publication Number Publication Date
CN104271142A CN104271142A (zh) 2015-01-07
CN104271142B true CN104271142B (zh) 2017-07-04

Family

ID=49083360

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380023492.XA Active CN104271142B (zh) 2012-03-01 2013-03-01 含有α连接蛋白C‑末端(ACT)肽的局部凝胶

Country Status (17)

Country Link
US (5) US8846605B2 (enExample)
EP (1) EP2819682B1 (enExample)
JP (1) JP6185937B2 (enExample)
KR (1) KR102038948B1 (enExample)
CN (1) CN104271142B (enExample)
AU (1) AU2013225716B2 (enExample)
BR (1) BR112014021653B1 (enExample)
CA (1) CA2866115C (enExample)
DK (1) DK2819682T3 (enExample)
IL (1) IL234380B (enExample)
IN (1) IN2014DN07420A (enExample)
MX (1) MX351881B (enExample)
NZ (1) NZ629769A (enExample)
RU (1) RU2657535C2 (enExample)
SG (1) SG11201405359YA (enExample)
WO (1) WO2013131040A1 (enExample)
ZA (1) ZA201406373B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0811530B1 (pt) 2007-05-14 2019-01-02 Research Foundation Of State Univ Of New York composição compreendendo indutor(es) de resposta fisiológica à dispersão ácido decanóico, superfície, solução, método ex vivo de tratamento ou inibição da formação de um biofilme sobre uma superfície
MX351881B (es) 2012-03-01 2017-11-01 Firststring Res Inc Geles tópicos que contienen péptidos de alfa-conexina c- terminal (act).
US11246821B2 (en) * 2016-08-30 2022-02-15 Rohm And Haas Company Personal care composition
ES2970509T3 (es) * 2017-02-16 2024-05-29 Xequel Bio Inc Composición y métodos para prevenir lesión por radiación y fomentar la regeneración tisular
SG11201907845SA (en) * 2017-06-14 2019-09-27 Biosolution Co Ltd Anti-wrinkle or anti-inflammatory cosmetic composition including substance p
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
KR20210057072A (ko) * 2018-09-12 2021-05-20 퍼스트스트링 리서치 인코포레이티드 알파 코넥신 c-말단 펩타이드에 대한 나노 입자 제제 및 사용 방법
RU2691647C1 (ru) * 2018-11-29 2019-06-17 Артем Иванович Трофименко Средство для профилактики образования патологических кожных рубцов
US11751056B2 (en) * 2020-08-31 2023-09-05 Oracle International Corporation Methods, systems, and computer readable media for 5G user equipment (UE) historical mobility tracking and security screening using mobility patterns
AU2021364900A1 (en) 2020-10-22 2023-06-08 Xequel Bio, Inc. Peptide formulations and ophthalmic uses thereof
US20250281574A1 (en) * 2022-04-29 2025-09-11 Xequel Bio, Inc. Compositions and methods for treating complications of viral infections and other respiratory disorders
CN117582401B (zh) * 2023-12-07 2024-04-26 唐宁医药科技(济南)有限公司 一种糖尿病足凝胶及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070104665A1 (en) * 2005-10-11 2007-05-10 Dfb Pharmaceuticals, Inc. Surfactant-free dispersions, compositions, and use in topical formulations
CN101151043A (zh) * 2004-12-21 2008-03-26 南卡罗来纳州医科大学研究发展基金会 促进伤口愈合和组织再生的组合物和方法
CN101198345A (zh) * 2005-06-17 2008-06-11 雷金纳克斯生物制药公司 用于治疗或阻止组织衰退、损伤或损害的lkktet和/或lkktnt组合物及方法
US20080299228A1 (en) * 2007-05-29 2008-12-04 Alan Gerald Harris Topical compositions comprising a macromolecule and methods of using same
WO2009085272A2 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Improved medical devices

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3603444A1 (de) * 1986-02-05 1987-08-06 Thomae Gmbh Dr K Pharmazeutische zubereitungsformen zur stabilisierung von interferon alpha
NZ235556A (en) 1986-11-05 1991-06-25 Ethicon Inc Breast milk substitute containing recombinant human egf
US5234809A (en) 1989-03-23 1993-08-10 Akzo N.V. Process for isolating nucleic acid
CA2080538A1 (en) * 1991-10-21 1993-04-22 Joseph V. Bondi Lyophilized acidic fibroblast growth factor
US5401504B1 (en) * 1993-12-28 1998-04-21 Univ Mississippi Medical Cente Use of tumeric in wound healing
FR2739621B1 (fr) 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
AU776512B2 (en) 1999-01-27 2004-09-09 David Laurence Becker Formulations comprising antisense nucleotides to connexins
WO2003014303A2 (en) 2001-08-03 2003-02-20 Arbor Vita Corporation Molecular interactions in cells
ES2436624T3 (es) 1999-05-14 2014-01-03 Arbor Vita Corporation Péptidos o análogos de péptidos para modulación de la fijación de una proteína PDZ y una proteína PL
US7250397B2 (en) 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
EP1387692A4 (en) 2000-11-11 2004-07-21 Arbor Vita Corp MOLECULAR INTERACTIONS IN HEMATOPOETIC CELLS
US7364750B2 (en) 2001-04-30 2008-04-29 The University Of British Columbia Autogene nucleic acids encoding a secretable RNA polymerase
US20050053918A1 (en) 2001-05-16 2005-03-10 Technion Research & Development Foundation Ltd. Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
CN1827766B (zh) 2001-06-28 2010-08-25 徐荣祥 体外细胞的培养方法
US6685971B2 (en) 2001-06-28 2004-02-03 Rongxiang Xu Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract
JP2005509621A (ja) 2001-10-17 2005-04-14 ユニバーシティ オブ ウェールズ カレッジ オブ メディスン ギャップ結合ならびにｅｄｈｆ
JP2003238441A (ja) 2002-02-08 2003-08-27 英行 ▲高▼野 血管新生抑制剤
US20030215424A1 (en) 2002-05-15 2003-11-20 Seul Kyung Hwan Method of modulating angiogenesis
IL152573A (en) * 2002-10-31 2009-11-18 Transpharma Medical Ltd A system for the transmission through the skin of a medical preparation against vomiting and nausea
WO2004073616A2 (en) 2003-02-14 2004-09-02 Human Matrix Sciences Llc Elastin digest compositions and methods utilizing same
DK1699924T3 (da) 2003-12-03 2019-10-21 Ocunexus Therapeutics Inc Connexin 43-målrettede hæmmende forbindelser og fremgangsmåder til anvendelse deraf i behandling af hornhindetraume
US9408381B2 (en) 2004-12-21 2016-08-09 Musc Foundation For Research Development Alpha Connexin c-Terminal (ACT) peptides for use in transplant
PL2289535T3 (pl) * 2004-12-21 2018-12-31 Musc Foundation For Research Development Kompozycje i sposoby wspomagania gojenia ran oraz regeneracji tkanek
AU2006257283A1 (en) 2005-02-03 2006-12-21 Coda Therapeutics Limited Anti-connexin compounds and uses thereof
KR20080021782A (ko) * 2005-06-17 2008-03-07 리지너크스 바이오 파마소티컬스, 인코포레이티드 엘케이케이티이티 및/또는 엘케이케이티엔티 펩티드조성물들 및 그 방법
GB0709513D0 (en) * 2007-05-17 2007-06-27 Helperby Therapeutics Ltd Topical formulations
US8247384B2 (en) 2006-11-15 2012-08-21 Coda Therapeutics, Inc. Methods and compositions for wound healing
EP2543377A1 (en) 2006-12-11 2013-01-09 Coda Therapeutics, INC. Anticonnexin polynucleotides as impaired wound healing compositions
JP5552048B2 (ja) 2007-06-21 2014-07-16 ムスク ファンデーション フォー リサーチ ディベロップメント 加齢性黄斑変性を治療するためのアルファコネキシンｃ末端（ａｃｔ）ペプチド
CA2592285C (en) 2007-06-28 2019-10-01 Musc Foundation For Research Development Compositions comprising connexin polypeptides and methods for promoting wound healing and tissue regeneration using connexin polypeptides
JP2011506446A (ja) * 2007-12-11 2011-03-03 コーダ セラピューティクス， インコーポレイテッド 損傷した創傷治癒組成物および治療
CN102920996A (zh) 2007-12-11 2013-02-13 科达治疗公司 受损伤口愈合的药物组合物
JP2011507856A (ja) 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 整形外科状態の治療のための抗コネキシンポリヌクレオチド、ペプチド、または抗体の使用
CA2710388A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides for the treatment of abnormal or excessive scars
AU2008343842A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of orthopedic conditions
CA2710232A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of abnormal or excessive scars
JP2011507855A (ja) 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 外科的癒着の治療のための、単独のまたは抗コネキシンポリヌクレオチドと組み合わせた抗コネキシンペプチドの使用
WO2009085273A2 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides for the treatment of surgical adhesions
JP2011507861A (ja) 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 線維症性の状態の治療のための抗コネキシンポリヌクレオチド剤と組み合わせた抗コネキシンポリペプチド剤の使用
AU2008343841A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of inhibitors of connexin43 for treatment of fibrotic conditions
CA2711635A1 (en) * 2008-01-07 2009-08-06 Coda Therapeutics, Inc. Wound healing compositions and treatments
CN102099475A (zh) 2008-06-04 2011-06-15 科达治疗公司 用间隙连接调节化合物治疗疼痛
EP2586436A1 (en) 2011-10-31 2013-05-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor
MX351881B (es) 2012-03-01 2017-11-01 Firststring Res Inc Geles tópicos que contienen péptidos de alfa-conexina c- terminal (act).

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101151043A (zh) * 2004-12-21 2008-03-26 南卡罗来纳州医科大学研究发展基金会 促进伤口愈合和组织再生的组合物和方法
CN101198345A (zh) * 2005-06-17 2008-06-11 雷金纳克斯生物制药公司 用于治疗或阻止组织衰退、损伤或损害的lkktet和/或lkktnt组合物及方法
US20070104665A1 (en) * 2005-10-11 2007-05-10 Dfb Pharmaceuticals, Inc. Surfactant-free dispersions, compositions, and use in topical formulations
US20080299228A1 (en) * 2007-05-29 2008-12-04 Alan Gerald Harris Topical compositions comprising a macromolecule and methods of using same
WO2009085272A2 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Improved medical devices

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
New therapeutics for the prevention and reduction of scarring;OCCLESTON N L 等;《DRUG DISCOVERY TODAY》;20081101;第13卷(第21-22期);第973-981页 *
Novel therapies for scar reduction and regenerative healing of skin wounds;RHETT等;《TRENDS IN BIOTECHNOLOGY》;20080304;第26卷(第4期);第173-180页 *

Also Published As

Publication number Publication date
EP2819682B1 (en) 2017-05-03
RU2657535C2 (ru) 2018-06-14
JP2015513549A (ja) 2015-05-14
MX2014010501A (es) 2015-03-09
MX351881B (es) 2017-11-01
CA2866115C (en) 2020-03-24
EP2819682A4 (en) 2016-01-06
AU2013225716B2 (en) 2017-10-12
US20130267471A1 (en) 2013-10-10
NZ629769A (en) 2016-09-30
ZA201406373B (en) 2015-12-23
WO2013131040A1 (en) 2013-09-06
KR20140132388A (ko) 2014-11-17
BR112014021653A2 (pt) 2022-05-10
SG11201405359YA (en) 2014-09-26
US8846605B2 (en) 2014-09-30
KR102038948B1 (ko) 2019-11-26
US11524049B2 (en) 2022-12-13
IN2014DN07420A (enExample) 2015-04-24
EP2819682A1 (en) 2015-01-07
HK1205451A1 (en) 2015-12-18
US20210128682A1 (en) 2021-05-06
DK2819682T3 (en) 2017-08-21
CA2866115A1 (en) 2013-09-06
RU2014139668A (ru) 2016-04-20
US20230263857A1 (en) 2023-08-24
AU2013225716A1 (en) 2014-09-18
US10632173B2 (en) 2020-04-28
US12128086B2 (en) 2024-10-29
US9161984B2 (en) 2015-10-20
CN104271142A (zh) 2015-01-07
IL234380B (en) 2020-10-29
JP6185937B2 (ja) 2017-08-23
US20160058834A1 (en) 2016-03-03
US20150018284A1 (en) 2015-01-15
BR112014021653B1 (pt) 2023-03-28

Similar Documents

Publication Publication Date Title
CN104271142B (zh) 含有α连接蛋白C‑末端(ACT)肽的局部凝胶
TWI670072B (zh) 凍乾的重組ｖｗｆ調配物
KR101752508B1 (ko) 제8 인자 제형
JP7145163B2 (ja) 放射線障害を予防し、組織再生を促進するための組成物および方法
US20240051997A1 (en) Sap and peptidomimetic compositions for reducing symptoms of inflammation
JP2018130552A (ja) 胆汁漏の処置
CN108883061A (zh) 稳定的液体促性腺激素制剂
US20200078489A1 (en) Pancreatic fistula occlusion
TW201204384A (en) Lactoferrin sequences, compositions and methods of wound treatment
HK1205451B (en) Topical gels containing alpha connexin c-terminal (act) peptides
JP2010536906A (ja) Ｇ−ｃｓｆの液体製剤
US20210023257A1 (en) Cerebrospinal fluid leakage occlusion
WO2021139901A1 (en) Peptide-containing composition for use for treating neoplastic lesions
US10195282B2 (en) Use of alginate formulation for intraincisional drug delivery

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1205451

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1205451

Country of ref document: HK